RUA Life Sciences Sees Strong Revenue Growth

RUA Life Sciences (GB:RUA) has released an update.

RUA Life Sciences reports a robust first-half revenue growth, doubling from last year, driven by increased biomaterials royalties and contract manufacturing revenues. The group’s strategic acquisition of Abiss Group has bolstered its financial standing, with a pre-tax profit of £0.4 million, a significant recovery from a loss last year. The company is also adjusting its accounting year to align better with business planning.

For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.